IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occu

MANAGEMENT PRESENTATION SEPTEMBER

21-25, 2020 Exhibit 99.1

IMPORTANT CAUTIONARY STATEMENT This

presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occur in the future are forward-looking statements, including,

without limitation, statements regarding the following: our expectations regarding third quarter results; our expectations regarding our ability to fund our ongoing and future operating costs, future growth, and future profitability; the regulatory

pathway for our products, including our existing and planned investigative new drug application and pre-market approval requirements, the design and success of our clinical trials and pursuit of biologic license applications ("BLAs") for

certain products; the timing of clinical trials, expected results of clinical trials, whether the FDA will approve future products and indications, and market acceptance of such products; the timing of planned international expansion, and regulatory

approval and market acceptance in those countries; our expectations regarding our ability to manufacture certain of our products in compliance with current Good Manufacturing Practices ("cGMP"); our expectations regarding costs relating

to compliance with regulatory standards, including those arising from our clinical trials, pursuit of BLAs, and cGMP compliance; our ability to continue marketing our micronized products and certain other products during and following the end of the

period of enforcement discretion announced by the United States Food and Drug Administration ("FDA"); expectations regarding future revenue growth and future research and development expenses; ongoing and future effects arising from the

COVID-19 pandemic and the Company's plans to adhere to governmental recommendations with respect thereto; and demographic and market trends. Forward-looking statements generally can be identified by words such as "expect,"

"will," "change," "intend," "seek," "target," "future," "plan," "continue," "potential," "possible," "could,"

"estimate," "may," "anticipate," "to be" and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could

significantly affect the Company's operations and may cause the Company's actual actions, results, financial condition, performance or achievements to differ materially. Factors that may cause such a difference include, without

limitation, those discussed under the heading "Risk Factors" in our most recent Form 10-Q and in our Form 10-K for the year ended December 31, 2019. Unless required by law, the Company does not intend, and undertakes no obligation, to

update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained

herein is specifically qualified in its entirety by the aforementioned factors. Non-GAAP Financial Measures This presentation includes non-GAAP financial measures to describe the Company's performance. Additional information and

reconciliations of those measures to GAAP measures are provided in the appendix to this presentation beginning at slide 34.

ADVANCED WOUND CARE AND THERAPEUTIC

BIOLOGICS COMPANY Pioneer with leading brands and a late-stage pipeline 40+ Scientific & clinical publications 1,900,000+ Allografts Distributed1 84% Gross Margin4 $281M Net Sales2 $711M Market Cap1 696 Employees3 Reimbursement coverage: 286M+

lives MDXG (OTC PINK) Founded in 2008 Total # patients studied under IND clinical programs7 1,000+ 5-year shelf life Room temp storage 300+ regulatory proteins 30M with diabetes5 (U.S.) 2.9M chronic wounds 11.2% prevalence of U.S. adults with

diagnosed diabetes6 (1) As of September 17, 2020; (2) Trailing twelve months period ended June 30, 2020, as reported in applicable SEC filings. Amount includes amounts recorded in net sales to reflect certain effects of the transition to revenue

recognition at the time of shipment. Refer to slide 22 f or more information; (3) As of December 31, 2019; (4) Represents gross margin for the trailing twelve months period ended June 30, 2020. (5) Sen CK. Human Wounds and Its Burden: An Updated

Compendium of Estimates. Adv Wound Care (New Rochelle). 2019;8(2):39-48. doi:10.1089/wound.2019.0946; (6) Lin, J., Thompson, T.J., Cheng, Y.J. et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metrics

16, 9 (2018). https://doi.org/10.1186/s12963-018-0166-4 (7) MiMedx IND Clinical Trial Programs; Plantar Fasciitis Phase 2B: 147; Plantar Fasciitis Phase 3: 276; Knee Osteoarthritis Phase 2B: 430+; Achilles Tendonitis Phase 3: 158. Strong Brand

ADVANCED WOUND CARE SECTOR IS LARGE AND

GROWING, WITH CONSIDERABLE UNMET NEED Source: Global Data 2019 Market Size and Growth Report: United States, Wound Care Management Market 2019. BioMed GPS SmartTrak; CAGR 2019-2024E U.S. Wound Care $3B are advanced wounds $12B 4% CAGR Growth

drivers: Aging population Growing prevalence of diabetes and chronic wounds Increasing number of wound care procedures Rising physician awareness of new treatment options Focus on clinical efficacy and cost effectiveness 6% CAGR $1B skin substitutes

6% CAGR $1B skin substitutes AMNIOTIC

TISSUE REPRESENTS LARGEST & FASTEST GROWING PORTION OF SKIN/DERMAL SUBSTITUTE MARKET Amniotic Tissue Allografts Xenograft Skin Substitutes ~$233M Others +8-10% CAGR U.S. Amniotic Tissue Market Source: BioMed GPS SmartTrak; CAGR 2019-2024E

Competitor A Others Competitor B Competitor C

TRANSFORMING THE BUSINESS 2021 + 2020

2019 New CEO New external auditor Debt financing New board members Key hires Restatement Resolution of SEC/VA cases Recapitalization Product launch Completed trial enrollment Profitable growth International expansion Pipeline maturation SUSTAIN

INVESTMENT HIGHLIGHTS 1 2 3 4 5 7 6

Leader in tissue-based products for advanced wound care Strong & differentiated infrastructure to deliver growth Versatile product offerings supported by robust clinical evidence Underserved, growing market opportunity Promising pipeline targets

unmet needs in large markets Experienced, new leadership team Business now positioned for sustainable & profitable growth

STRONG AND DIFFERENTIATED

INFRASTRUCTURE TO DELIVER GROWTH 40+ clinical & scientific publications in peer-reviewed, indexed journals Best-in-class evidence recognized by AHRQ1 Robust publication strategy with accompanying medical education support Universal tissue with

broad applicability Proprietary process provides power, quality, safety & product logistics Broad protection for core & growth technologies, including trade secrets Span of control from recovery to distribution managed by direct employees

Rigorous quality manufacturing process with attractive gross margins Geographically distributed and scalable placenta donation & recovery network Experienced sales team with extensive reach & established customer relationships Reimbursement

coverage of 286+ million lives (Medicare, Medicaid, Commercial) Current multi-year contracts, including commitment tier, with largest GPOs2 BODY OF EVIDENCE MARKET-LEADING PLATFORM VERTICALLY INTEGRATED COMMERCIAL SCALE (1) Agency for Healthcare

Research and Quality; (2) Group Purchasing Organizations

THE PLACENTA IS A SOPHISTICATED

BIOLOGICAL SYSTEM THAT SUPPORTS GROWTH AND HEALING Demonstrated Power of the Placenta EpiFix in Venous Leg Ulcer (VLU) Day 42 Day 1 Day 7 Day 35 EpiFix in Diabetic Foot Ulcer (DFU) Regulator of angiogenesis2 Modulates inflammation Barrier membrane

Inhibitor of fibrosis and scars Promoter of epithelialization3 Non-immunogenic material Known Properties of Amniotic Tissue1 (1) N. G. Fairbairn, M. A. Randolph, R. W. Redmond, J Plast Reconstr Aesthet Surg. 2014 May; 67(5):

662-675. Published online 2014 Jan 31. doi: 10.1016/j.bjps.2014.01.031; (2) Angiogenesis is the formation of new blood vessels. This process involves the migration, growth, and differentiation of endothelial cells, which line

the inside wall of blood vessels; (3) Epithelialization is an essential component of wound healing used as a defining parameter of a successful wound closure

VERSATILE PLATFORM WITH BROAD

POTENTIAL ACROSS MULTIPLE APPLICATIONS new! (1) 361 HCT/Ps (Human Cell Tissue/ Products) for homologous use only; HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's

objective intent. As defined in 21 CFR 1271.3(c), homologous use means the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissues with an HCT/P that performs the same basic function or functions in the

recipient as in the donor. (2) Clinical trials in planning or underway; Final indication for use to be confirmed at FDA product approval. Amnion/Chorion Umbilical Cord Placental Tissue Matrix Injectable Amnion/Chorion Applications1: Acute &

Chronic Wounds Diabetic Foot Ulcers Venous Leg Ulcers Applications1: Acute & Chronic Wounds Diabetic Foot Ulcers Venous Leg Ulcers Indications2: Soft Tissue Defects Indications2: Musculoskeletal & Sports Medicine: Knee Osteoarthritis Plantar

Fasciitis Advanced Wound Care: Chronic Wounds Surgical Incisions

CLINICAL EVIDENCE DEMONSTRATES

DIFFERENTIATION & SUPPORTS REIMBURSEMENT Statistically significant results* Randomized controlled trials across multiple applications Head-to-head study results demonstrate superior clinical outcomes & substantially lower cost-to-closure

compared to Apligraf Studies demonstrate Low Risk of Bias* *Skin Substitutes for Treating Chronic Wounds Technical Brief; Technology Assessment Program; Agency for Healthcare Research and Quality, Feb 2, 2020 **Please see Appendix for Clinical

Study Summary and references; "intended to help health care decision makers - patients and clinicians, health system leaders, and policymakers, among others - make well-informed decisions and thereby improve the quality of health

care services" VALIDATION OF DATA IN RECENT AHRQ* REPORT BEST-IN-CLASS CLINICAL EVIDENCE **

DONATION PROGRAM PROTECTS QUALITY

WITH INTEGRATED SUPPLY AND DELIVERY NETWORK 1 2 3 4 5 6 7 Expectant Mom Introduced to Donation Program Mom Consents to Donate; Completes Medical History & Risk Assessment Questionnaire Delivery of Healthy Baby via Caesarean Section

Micro-biological & Viral Testing of Donor Tissue Donated Placental Tissues Recovered Proprietary Processing and Terminal Sterilization Shelf-stable Packaged Product 75,000+ Placentas Recovered1 1.9+ million Allografts Distributed1 <0.01%

Reported Events1 (1) As of September 17, 2020

INVEST COMMERCIALLY TO DRIVE GROWTH

ADVANTAGED BY STRONG INFRASTRUCTURE Enhance Sales Effectiveness New commercial leadership Structure, deployment and scale Value-based selling Invest in Market Development Medical education Brand & digital assets New products Highlight

Differentiation from Competition Clinical evidence Contract positions Health economic data Invest and Execute for Growth Leverage Commercial Infrastructure Scale Field-based sales team Independent agent network Inside sales team Relationship Across

care continuum Multiple specialties 2,500+ physician users for Medicare patients in Outpatient setting Reach and Access 4,000+ customers Favorable contracts with top 3 GPO's 286+ million covered lives Support Field-based reimbursement support

team 50,000+ patients supported annually with insurance verification requests

TARGETED INVESTMENT FOR GEOGRAPHIC

EXPANSION UK GERMANY JAPAN Total Wound Care Market ~$380M ~$740M ~$430M DFU + VLU 225K 500K 650K MiMedx Addressable Market 35K 80K 100K Regulatory Status Approved Approved Anticipated 2021 Reimbursement Status In process In process 3-6 months

post-approval Current primary market 1-2 year expansion 2-3 year expansion Source: Global Data Tissue Engineered - Skin Sub Data Model Wound Management Japan, Germany and UK Year 2020_ retrieved Sept 2020; Management estimates; MiMedx

Addressable Market represents assumed, eventual 15% penetration of the addressable market. Reaching this level is subject to numerous risks and uncertainties, including regulatory and market acceptance, and appropriate reimbursement. Investors are

cautioned that actual results may differ materially.

Existing Core Business Drive disease

state awareness across care continuum Publish additional data Expand into additional wound applications FOUR KEY DRIVERS TO ACHIEVE CORE GROWTH Portfolio Expansion Advance market assessments and analytics Leverage clinical and regulatory expertise

Invest in prioritized new markets Maximize core business Enhance sales force productivity and commercial analytics Highlight clinical and economic value Continue product innovation Explore additional priority markets Identify wound care adjacencies

PURSUE INTERNATIONAL EXPANSION ENHANCE PORTFOLIO VALUE TARGET NEW BUSINESS EXPAND THE MARKET 2 1 3 4

LATE-STAGE PIPELINE LEVERAGES

LEADERSHIP IN PLACENTAL SCIENCE Potential to address unmet patient needs as a platform technology across multiple markets * Clinical study initiation will depend on FDA feedback for program PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 MUSCULOSKELETAL/SPORTS

MEDICINE Plantar Fasciitis (PF) Achilles Tendonitis (AT) Knee Osteoarthritis (KOA) ADVANCED WOUND CARE Chronic Wounds* Surgical Incisions* Soft Tissue Defects*

2020 2021 2022 2023 2024 2025 1H 2H

1H 2H 1H 2H 1H 2H 1H 2H 1H 2H INJECTABLE AMNION-CHORION Plantar Fasciitis Achilles Tendonitis Knee Osteoarthritis LATE STAGE CLINICAL PROGRAMS MATURING PHASE 3 PHASE 2 PHASE 3 LPI LPO LPI LPO LPI = last patient in LPO = last patient out End of

Enforcement Discretion Estimated BLA Filing Estimated BLA Approval BLA Filing dependent on data readout According to recently updated FDA guidance, FDA generally intends to exercise enforcement discretion through May 31, 2021, with respect to the

IND and the premarket approval requirements for certain HCT/Ps, provided that use of the HCT/P does not raise reported safety concerns or potential significant safety concerns.; Timeline represents current plans and estimates only. Actual results

and timing may differ materially. There can be no assurance that clinical trials are conducted or completed on schedule, that trial results are favorable, or that we obtain regulatory approval for our products and indications PHASE 3 LPI

PLANNED IND / IDE FILINGS BROADEN

PIPELINE 2020 2021 2022 2023 1H 2H 1H 2H 1H 2H 1H 2H INJECTABLE AMNION-CHORION Chronic Wounds Surgical Incisions PLACENTAL TISSUE MATRIX Soft Tissue Defects Proof of Concept IND / IDE Filing Proof of Concept IND Enabling Studies IND Enabling Studies

IND Enabling Studies Proof of Concept IND = Investigational New Drug IDE = Investigational Device Exemption End of Enforcement Discretion According to recently updated FDA guidance, FDA generally intends to exercise enforcement discretion through

May 31, 2021, with respect to the IND and the premarket approval requirements for certain HCT/Ps, provided that use of the HCT/P does not raise reported safety concerns or potential significant safety concerns.; Timeline represents current plans and

estimates only. Actual results and timing may differ materially. There can be no assurance that clinical trials are conducted or completed on schedule, that trial results are favorable, or that we obtain regulatory approval for our products and

PF STUDY INFORMS SAFETY, EFFICACY

AND OTHER FUTURE INDICATIONS (1) Tong KB, Furia J. Economic burden of plantar fasciitis treatment in the United States. Am J Orthop (Belle Mead NJ). 2010;39(5):227-231; (2) Ang TW. The effectiveness of corticosteroid injection in the treatment

of plantar fasciitis. Singapore Med J. 2015;56(8):423-432. doi:10.11622/smedj.2015118; (3) Plantar Fasciitis Primary Research/Conjoint Analysis (n=171) performed by Market Vision December 2019 https://www.mv-research.com/ (data on file). Plantar

Fasciitis (PF) 2M+ U.S. Patients treated for PF annually1 200K+ Candidates for advanced therapies2 ~20K-50K Potential candidates for injectable amnion/ chorion3 Conservative (RICE/NSAIDS) Custom orthotics Corticosteroid injections Emerging therapies

Current Treatments Recovery for chronic PF tends to be lengthy and recurrence is common

RETROSPECTIVE STUDY PROVIDED INSIGHT

INTO POTENTIAL FOR REDUCING PAIN AND IMPROVING FUNCTION Knee Osteoarthritis (KOA) (1) Alden KJ, Harris S, Hubbs B, Kot K, Istwan NB, Mason D. Micronized Dehydrated Human Amnion Chorion Membrane Injection in the Treatment of Knee Osteoarthritis-A

Large Retrospective Case Series [published online ahead of print, 2019 Nov 28]. J Knee Surg. 2019;10.1055/s-0039-3400951. doi:10.1055/s-0039-3400951. (2) OARSI (Osteoarthritis Research Society International) Dec, 2016. (3) Murphy L, Schwartz

TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207-1213. doi:10.1002/art.24021; (4) US Bone and Joint Initiative. The Burden of Musculoskeletal Diseases in the United States (BMUS).

https://www.boneandjointburden.org/fourthedition/iiib10/osteoarthritis. Accessed August 2020. Injectable Amnion / Chorion (mdHACM) in the Treatment of KOA1 Evaluated 82 KOA patients and 100 knees injected with 100mg mdHACM by a single physician,

over a 14-month period Represents largest single-physician experience with injectable amniotic tissue for treatment of KOA reported to date Findings: mdHACM injection clinically effective in reducing pain and improving function in the setting of KOA